Imiquimod and Pulmonary Embolism: a Case Report

Leroy, B.; Richez, Antoine; Wolf, François; Descotes, Jacques; Vial, Thierry

doi:10.2515/therapie/2013075

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe side effects including retinal vein occlusion (following treatment of a periorbital BCC), bilateral pulmonary embolism, and permanent vitiligo-like depigmentation were also reported. [22][23][24] In this study, mild to moderate local skin irritation was commonly observed. Although hypopigmentation/ depigmentation did develop on healing lesions, that depigmentation was temporary.…”

Section: Discussionmentioning

confidence: 62%

Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma

Bostancı¹,

Koçyiğit²,

Vural³

et al. 2018

Dermatol Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 62%

Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma

Bostancı¹,

Koçyiğit²,

Vural³

et al. 2018

Dermatol Surg

View full text Add to dashboard Cite

show abstract

“…Recurrence aside, there have been several reports of Imiquimod triggering keratoacanthomas and indeed infiltrating or aggressive SCC [ 22 ]. There has been also a report of a pulmonary embolism occurring after Imiquimod use [ 23 ]. The exact mechanism of inducing tumours remains unknown, although the exuberant immunological response is blamed—a sort of fighting “fire with fire” when utilizing immune-modulating agents that stimulate apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Melanoma Arising after Imiquimod Use

Paul

2014

Case Reports in Medicine

View full text Add to dashboard Cite

Imiquimod belongs to the class of 1H-imidazo-[4,5-c]quinolones—drugs originally developed as nucleoside analogues with the aim of finding new potential antiviral agents (Harrison et al., 1988). Indeed, Imiquimod was first released as treatment for genital warts before its actions against skin cancer were studied. Imiquimod is a relatively small sized molecule (Mr = 240.3) and is hydrophobic, allowing it to penetrate the skin epidermal barrier and therefore making it suitable for topical formulations (Gerster et al., 2005). Imiquimod has shown itself effective against skin cancers and precancerous lesions, especially basal cell cancers and actinic keratosis (Salasche et al., 2002, Beutner et al., 1999). There have been reports of Imiquimod being used as topical treatment against cutaneous metastases of melanoma and some authors have reported its use as first-line therapy against melanoma in situ (Smyth et al., 2011, Gagnon, 2011). We report a case of an invasive malignant melanoma arising de novo at the specific site of application of Imiquimod (Aldara cream 5%) for a biopsy-proven superficial BCC. Therefore while Imiquimod has added to our topical armamentarium against skin cancer, care must be exercised in prescribing this treatment and it is especially important to follow up patients regularly.

show abstract

Imiquimod

2014

Reactions Weekly

View full text Add to dashboard Cite

Imiquimod and Pulmonary Embolism: a Case Report

Cited by 3 publications

References 12 publications

Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma

Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma

Melanoma Arising after Imiquimod Use

Imiquimod

Contact Info

Product

Resources

About